Friday, June 29, 2018

IL-1 blockade with canakinumab reduces gout flares


Treatment with the immunomodulatory agent canakinumab reduces the risk of gout flares by more than half in patients with atherosclerosis, according to a post hoc analysis of the CANTOS* trial.

No comments:

Post a Comment